XTCY — Xtacy Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$2.33m
- CA$2.34m
Annual balance sheet for Xtacy Therapeutics, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.018 | 0.004 | 0.026 | 0 | — |
| Net Total Receivables | 0.024 | 0 | — | — | 0.084 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.043 | 0.004 | 0.026 | 0.298 | 0.102 |
| Long Term Notes Receivable | |||||
| Total Assets | 0.769 | 0.004 | 0.026 | 0.298 | 0.367 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.16 | 0.265 | 0.466 | 0.721 | 0.686 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.16 | 0.265 | 0.543 | 0.746 | 0.703 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 0.61 | -0.261 | -0.517 | -0.449 | -0.336 |
| Total Liabilities & Shareholders' Equity | 0.769 | 0.004 | 0.026 | 0.298 | 0.367 |
| Total Common Shares Outstanding |